Navigation Links
Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
Date:9/28/2007

ROCHESTER, Minn., Sept. 28 /PRNewswire-USNewswire/ -- A Mayo Clinic review of patients' responses to a drug used to control nausea and vomiting during anesthesia for general surgery questions a U.S. Food and Drug Administration (FDA) warning against the drug's use. This study appears in the current issue of the journal Anesthesiology.

The FDA warning against droperidol was prompted in 2001 over concerns that the drug contributed to potentially fatal heart rhythm abnormalities. Mayo Clinic compared 139,932 patients' responses before the warning was issued (and droperidol was used) and found no proven cases of complications directly attributable to droperidol. In comparison, after the FDA warning, two of 151,256 patients had poor heart rhythm while receiving other, more expensive medication alternatives. The percentage of patients who received droperidol was 12 percent prior to the warning and 0 percent after placement of the warning.

Based on their findings, Mayo Clinic anesthesiologists conclude that the FDA warning against droperidol is unnecessary. They call for other investigators to study the topic to determine if further inquiry supports that conclusion.

"In our study, we obtained results that were just the opposite of what the FDA action would predict. We actually had fewer complications with droperidol," explains Gregory Nuttall, M.D., the lead Mayo Clinic anesthesiologist on the study. "In our experience, low-doses of droperidol used by a skilled team are the safer and more effective agent for controlling nausea and vomiting, which is why we are making plans to resume its low-dose use in select patients in the cardiac Intensive Care Unit."

Significance of the Mayo Clinic Study

The Mayo Clinic study is the first large, statistically well-controlled study of patient responses to droperidol at a single medical center over a long time (three years) that included treatment before and after the FDA warning. As such, it pro
'/>"/>

SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... , ... June 29, 2015 , ... San Fernando ... lift and tighten sagging skin. Ulthera is a special treatment that offers a way ... ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted and precise to ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released the ... French consumers. , The specialized eye health formulation contains a variety of ingredients ... In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, ...
(Date:6/29/2015)... ... June 29, 2015 , ... Blue Cross and Blue ... the Commercial Markets division, which includes the company’s commercial health plan portfolio of ... regional, national and international reach. Mary Ellen Anderson now holds the title of ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... guided, safe, informed, responsible and legal access to Health Canada's medical cannabis program, ... NAC provides education on how Health Canada's medical marijuana system works. Members are ...
(Date:6/29/2015)... ... June 29, 2015 , ... Visiting retirement communities and ... that guide families on their search for senior care on http://www.SeniorsGuideOnline.com . , ... used during tours of assisted living , rehab, and nursing home communities ...
Breaking Medicine News(10 mins):Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 2Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 3Health News:New Checklists and Question Sheets for Visiting Retirement Communities, Interviewing Home Health Caregivers Available From Seniors Guide 2Health News:New Checklists and Question Sheets for Visiting Retirement Communities, Interviewing Home Health Caregivers Available From Seniors Guide 3
... preliminary study suggests that patients with cancer in the ... some driving skills compared with individuals without the disease, ... Archives of Otolaryngology-Head & Neck Surgery, one of the ... requires adequate cognitive, psychomotor and visuoperceptualmotor functions that work ...
... following public,service announcement is being issued by FMQAI: ... a time.,You could be that person. The Every Diabetic ... Community Health Workers and,conduct a diabetes education program. ... your place in this free, two and a half-day ...
... Metropolitan Jewish Geriatric Center,(MJGC) is proud to welcome Alla ... Lerner brings valuable experience as well as a familiarity,with ... been a unit,social worker at Shorefront Jewish Geriatric Center ... be responsible for overseeing the Social,Work Department at MJGC. ...
... Genomic,Health, Inc. (Nasdaq: GHDX ) today ... Chief Executive Officer, will present at the,ThinkEquity Partners ... on,September 18, 2007 at 8:00 a.m. Pacific Time. ... webcast of the,presentation, visit the Investor Relations section ...
... Over $1 Million From Insurers, Would Force All Americans,to ... The,Foundation for Taxpayer and Consumer Rights (FTCR) today ... a gift to,insurers that have given over $1 million ... that a plan that would require every American to ...
... pain, but not all doctors endorse it , , MONDAY, ... a gallbladder through a woman,s vagina, joining a handful ... novel technique, because it eliminates visible scarring and minimizes ... in New York City performed a similar operation, and, ...
Cached Medicine News:Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference 2Health News:Consumer Group: Hillary Clinton's Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Can't Afford $12k Policy 2Health News:Consumer Group: Hillary Clinton's Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Can't Afford $12k Policy 3Health News:Surgeons Remove Gallbladder Through Vagina 2Health News:Surgeons Remove Gallbladder Through Vagina 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: